The European human biospecimen market is projected to grow at an 8.24% CAGR from $881.8 million in 2025 to $1.94 billion by 2035, driven by increasing demand for precision medicine, oncology research, and expanding biobanks. Growth is supported by rising pharmaceutical R&D spending and EU-funded initiatives, though...
The global intravenous immunoglobulin (IVIG) market is projected to grow from USD 14.98 billion in 2025 to USD 30.83 billion by 2035, at a CAGR of 7.49%. Growth is driven by expanding neurological indications, increased plasma collection capacity, and rising demand for immunoglobulin-based treatments. However, plasma...
The global botulinum toxin in urology market is projected to grow from USD 1.1 billion in 2025 to USD 1.98 billion by 2035, at a CAGR of 6.08%. Growth is driven by increasing prevalence of urological disorders, aging populations, preference for minimally invasive treatments, and advancements in injection techniques....
The hepatic encephalopathy market is projected to grow at 1.2% CAGR through 2036, valued at USD 900 million in 2025. Growth is driven by rising prevalence of chronic liver diseases, improved early diagnosis awareness, and emerging therapies from companies like Vedanta Biosciences, Yaqrit Discovery Ltd, and others. The...
Canadian health care advocates are calling for the closure of Grifols plasma collection facilities and a public takeover following two deaths in Winnipeg linked to plasma sales, a third lawsuit for kidney damage, and Health Canada reports of non-compliance at four additional Grifols sites.
Pegasys market is poised for significant growth driven by rising hepatitis B prevalence, increasing healthcare spending, and expansion into oncology and hematology indications. However, the market faces headwinds from the rise of direct-acting antivirals and tariff-related cost pressures. North America leads in market...
The global Plasbumin-5 market is experiencing significant growth driven by rising surgical procedures, burn injuries, and expanding critical care infrastructure. North America leads the market while Asia-Pacific is the fastest-growing region. Grifols Therapeutics, the key market player, has strengthened its position...
The global blood plasma derivatives market is expected to double from $52.16 billion in 2025 to $104.30 billion by 2033, growing at a 9.08% CAGR. Growth is driven by increasing immune deficiencies, hematological disorders, and neurological conditions, with immunoglobulins representing 41.28% of the market. North...
The global plasma derived medicine market is projected to grow from $17.24 billion in 2024 to $37.4 billion by 2034, driven by increasing demand for therapies treating rare and immune disorders, with North America currently dominating the market.
The report examines the trends shaping the orphan designated drugs market, including healthcare, technology, macroeconomic, and regulatory factors. It provides insights into leading players and future challengers across the value chain, as well as key drugs and markets.
The global intravenous solutions market is projected to grow at a CAGR of 8.0% from 2024 to 2031, driven by the increasing elderly population, rising rates of chronic diseases, and advancements in medical technology.
The global infectious disease diagnostics market is projected to reach $43.09 billion by 2031, growing at a CAGR of 8.20% during the forecast period. The market is driven by advancements in diagnostic technologies, rising cases of infectious diseases, and increased R&D funding.
The global RFID Kanban systems market is expected to reach $9.53 billion by 2030, driven by increasing demand for real-time asset and inventory tracking. North America, particularly the U.S. hospital inventory management market, is expected to see high growth potential for RFID Kanban solutions.
BARCELONA, Spain, July 01, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world’s leading producers of plasma-derived medicines, today announced that Biotest, a Grifols Group company, forecasts approximately USD 1 billion in revenue from sales in the United States of its intravenous...
BARCELONA, Spain, June 18, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced it has completed the sale of a 20% equity stake in Shanghai RAAS (SRAAS) to Haier Group Corporation (Haier Group) and forged...
BARCELONA, Spain, June 17, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world’s leading producers of plasma-derived medicines, today announced that Biotest, a Grifols Group company, has received approval from the United States Food and Drug Administration (FDA) for Yimmugo®, an...
BARCELONA, Spain, April 18, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today officially celebrated the 50th anniversary of its flagship site in Clayton, N.C., whose production of these essential therapeutics...
U.S. stock futures were lower this morning, with the Dow futures falling over 150 points on Thursday. Shares of CarMax, Inc. (NYSE: KMX) fell sharply in today’s pre-market trading after the company reported lower-than-expected fourth-quarter earnings. CarMax posted quarterly earnings of 32 cents per share, missing...
Smart Beta ETF report for FBT
BARCELLONA, Spagna, April 04, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), uno dei principali produttori mondiali di farmaci plasmaderivati e di soluzioni diagnostiche innovative, ha annunciato in data odierna che il suo nuovo Procleix ArboPlex Assay ha ottenuto il marchio CE ai sensi della...
Headlines via Polygon.io. Links open the original publisher.